First Horizon Advisors Inc. Has $59,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

First Horizon Advisors Inc. raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 73.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 439 shares of the life sciences company’s stock after buying an additional 186 shares during the quarter. First Horizon Advisors Inc.’s holdings in Illumina were worth $59,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the stock. WCM Investment Management LLC lifted its stake in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after buying an additional 867,673 shares during the period. Geode Capital Management LLC lifted its stake in Illumina by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after buying an additional 48,018 shares during the period. Primecap Management Co. CA raised its position in shares of Illumina by 3.6% during the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after purchasing an additional 87,599 shares during the period. Janus Henderson Group PLC raised its position in shares of Illumina by 40.5% during the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after purchasing an additional 625,245 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Illumina by 4.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company’s stock worth $164,334,000 after purchasing an additional 54,319 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Down 5.4 %

ILMN stock opened at $88.97 on Friday. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average price of $124.32 and a two-hundred day moving average price of $133.21. The company has a market cap of $14.09 billion, a price-to-earnings ratio of -11.58, a P/E/G ratio of 1.60 and a beta of 1.10. Illumina, Inc. has a twelve month low of $88.75 and a twelve month high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. Piper Sandler raised their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. Guggenheim dropped their price target on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Morgan Stanley dropped their price target on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. raised their price target on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $159.45.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.